Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year... Read more »
Sarepta Therapeutics CEO Ed Kaye described Tuesday the ups and downs the Cambridge, MA, company has had as it tries to roll out eteplirsen (Exondys 51), the first-ever approved drug for... Read more »
New York State Governor Andrew Cuomo is planning to use some of the cash from his recently announced $650 million biotech initiative on Manhattan’s biggest life sciences problem—lack of lab space.... Read more »
Merrimack Pharmaceuticals is starting off the year with significant changes. The Cambridge, MA, company has decided to sell its only marketed products—a pair of cancer drugs—to pay off debt and invest... Read more »
[Updated, 2:37 pm ET] Two years ago, almost to the day, Foundation Medicine celebrated its biggest announcement ever. Roche had just paid more than $1 billion for a majority... Read more »
This past Christmas weekend, Ana Memedovich had her best two days in more than a decade.
Her 23-year-old son Mikhail has spinal muscular atrophy, or SMA, a rare genetic disease that... Read more »
Julian Adams, renowned for inventing bortezomib (Velcade), a drug that revolutionized multiple myeloma treatment years ago, is retiring from his role as president of research and development at Cambridge, MA-based Infinity... Read more »
RaNA Therapeutics is branching out. Today, the Cambridge, MA, startup is acquiring some assets from pharmaceutical giant Shire that immediately make it a player in an emerging, yet unproven field of... Read more »
Inotek Pharmaceuticals has started 2017 with a big setback.
The company’s first big Phase 3 test of an experimental glaucoma drug fell far short this morning, leaving the fate of the... Read more »
Even though Jounce Therapeutics has no human clinical data to report yet, a partnership with Celgene and support from a broad group of investors have made the Cambridge, MA, cancer drug... Read more »
The idea that New York City could become a biotech powerhouse dates back to the late 1990s. It’s been a slow, tedious process, and it’s nowhere near complete, but from near... Read more »
Patients with spinal muscular atrophy got an early Christmas present on Friday. The FDA approved nusinersen (Spinraza), making the drug the first-ever marketed treatment for the rare, potentially deadly genetic disorder.... Read more »
[Updated, 4:28 pm ET, see below] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical... Read more »
Akebia Therapeutics is in a high-stakes race with rival Fibrogen to treat anemia with a pill, not an injectable biologic. And it just got a bunch of cash to try to... Read more »
Slowly but surely, a new group of drugs known as “PARP” inhibitors are starting to become fixtures in the regimens for women with ovarian cancer—and perhaps more. With the approval of... Read more »
New York City Deputy Mayor Alicia Glen said it best: “It’s about creating what I call a ‘New York gestalt’ around life sciences.” Showing that New York biotech can rise above... Read more »
Ophthotech’s attempt to change the standard of care for a common form of vision loss, age related macular degeneration, fell short earlier this week, sending shares spiraling downward and leaving the... Read more »
Agios Pharmaceuticals has been developing two experimental drugs for anemia. For a couple of years, the company has said it would eventually move the better one forward and leave the other... Read more »
[Updated w/comments, new information, 3:45 p.m. ET, see below] Over the last two days, city and state governments in New York have combined to commit a total of $1.15... Read more »
December 15, 2016
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.